Thyroglobulin Peptides Associate In Vivo to HLA-DR in Autoimmune Thyroid Glands1

Endocrine epithelial cells, targets of the autoimmune response in thyroid and other organ-specific autoimmune diseases, express HLA class II (HLA-II) molecules that are presumably involved in the maintenance and regulation of the in situ autoimmune response. HLA-II molecules thus expressed by thyroid cells have the “compact” conformation and are therefore expected to stably bind autologous peptides. Using a new approach to study in situ T cell responses without the characterization of self-reactive T cells and their specificity, we have identified natural HLA-DR-associated peptides in autoimmune organs that will allow finding peptide-specific T cells in situ. This study reports a first analysis of HLA-DR natural ligands from ex vivo Graves’ disease-affected thyroid tissue. Using mass spectrometry, we identified 162 autologous peptides from HLA-DR-expressing cells, including thyroid follicular cells, with some corresponding to predominant molecules of the thyroid colloid. Most interestingly, eight of the peptides were derived from a major autoantigen, thyroglobulin. In vitro binding identified HLA-DR3 as the allele to which one of these peptides likely associates in vivo. Computer modeling and bioinformatics analysis suggested other HLA-DR alleles for binding of other thyroglobulin peptides. Our data demonstrate that although the HLA-DR-associated peptide pool in autoimmune tissue mostly belongs to abundant ubiquitous proteins, peptides from autoantigens are also associated to HLA-DR in vivo and therefore may well be involved in the maintenance and the regulation of the autoimmune response.

[1]  E. Unanue,et al.  First Signature of Islet β-Cell-Derived Naturally Processed Peptides Selected by Diabetogenic Class II MHC Molecules1 , 2008, The Journal of Immunology.

[2]  H. Rammensee,et al.  Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. , 2007, The Journal of clinical investigation.

[3]  H. Rammensee,et al.  Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas , 2006, Clinical Cancer Research.

[4]  Lars Fugger,et al.  MHC class II proteins and disease: a structural perspective , 2006, Nature Reviews Immunology.

[5]  F. Aloisi,et al.  Lymphoid neogenesis in chronic inflammatory diseases , 2006, Nature Reviews Immunology.

[6]  F. Koning,et al.  Dissection of the HLA-DR4 Peptide Repertoire in Endocrine Epithelial Cells: Strong Influence of Invariant Chain and HLA-DM Expression on the Nature of Ligands1 , 2004, The Journal of Immunology.

[7]  Vladimir Brusic,et al.  Pathogenic human thyroglobulin peptides in HLA-DR3 transgenic mouse model of autoimmune thyroiditis. , 2004, Cellular immunology.

[8]  Hans-Georg Rammensee,et al.  MHC ligands and peptide motifs: first listing , 2004, Immunogenetics.

[9]  Y. Tomer,et al.  Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. , 2003, Endocrine reviews.

[10]  G. Carayanniotis The Cryptic Self in Thyroid Autoimmunity: The Paradigm of Thyroglobulin , 2003, Autoimmunity.

[11]  M. Alvarez-Silva,et al.  Thyroid hormone modulates the extracellular matrix organization and expression in cerebellar astrocyte: Effects on astrocyte adhesion , 2003, Glia.

[12]  N. Oshitani,et al.  Analysis of intestinal HLA-DR bound peptides and dysregulated immune responses to enteric flora in the pathogenesis of inflammatory bowel disease. , 2003, International journal of molecular medicine.

[13]  A. Weetman Autoimmune thyroid disease: propagation and progression. , 2003, European journal of endocrinology.

[14]  W. Savino,et al.  Triiodothyronine Modulates Extracellular Matrix-Mediated Interactions between Thymocytes and Thymic Microenvironmental Cells , 2002, Neuroimmunomodulation.

[15]  F. Koning,et al.  HLA-DR4 Molecules in Neuroendocrine Epithelial Cells Associate to a Heterogeneous Repertoire of Cytoplasmic and Surface Self Peptides1 , 2002, The Journal of Immunology.

[16]  Wilfred F. van Gunsteren,et al.  Computation of free energy , 2002 .

[17]  G. Carayanniotis,et al.  Enhanced Iodination of Thyroglobulin Facilitates Processing and Presentation of a Cryptic Pathogenic Peptide1 , 2002, The Journal of Immunology.

[18]  Q. Wan,et al.  HLA-DR and HLA-DQ polymorphism in human thyroglobulin-induced autoimmune thyroiditis: DR3 and DQ8 transgenic mice are susceptible. , 2002, Human immunology.

[19]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[20]  M. Juan,et al.  Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. , 2001, The American journal of pathology.

[21]  Wilfred F. van Gunsteren,et al.  An improved GROMOS96 force field for aliphatic hydrocarbons in the condensed phase , 2001, J. Comput. Chem..

[22]  M. Puzianowska-Kuźnicka,et al.  Differential regulation of three thyroid hormone‐responsive matrix metalloproteinase genes implicates distinct functions during frog embryogenesis , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Andrew E. Torda,et al.  The GROMOS biomolecular simulation program package , 1999 .

[24]  M. Sospedra,et al.  HLA-DM and invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules. , 1999, International immunology.

[25]  C. Nelson,et al.  Structural principles of MHC class II antigen presentation. , 1999, Reviews in immunogenetics.

[26]  M. Juan,et al.  Transcription of a broad range of self-antigens in human thymus suggests a role for central mechanisms in tolerance toward peripheral antigens. , 1998, Journal of immunology.

[27]  T. Bednarczuk,et al.  T cell interactions with extracellular matrix proteins in patients with thyroid-associated ophthalmopathy. , 1998, Autoimmunity.

[28]  C. Jarzynski Nonequilibrium Equality for Free Energy Differences , 1996, cond-mat/9610209.

[29]  P. Santisteban,et al.  Amino acid composition of proteins extracted from endemic goiter glands , 1996, Endocrine pathology.

[30]  Paul Wordsworth,et al.  Purification and characterization of endogenous peptides extracted from HLA‐DR isolated from the spleen of a patient with rheumatoid arthritis , 1995, European journal of immunology.

[31]  M. Sospedra,et al.  Hyperinducibility of HLA class II expression of thyroid follicular cells from Graves' disease. A primary defect? , 1995, Journal of immunology.

[32]  H. Rammensee,et al.  Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. , 1994, Journal of immunology.

[33]  William Arbuthnot Sir Lane,et al.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles , 1993, The Journal of experimental medicine.

[34]  G. Carayanniotis,et al.  Induction of experimental autoimmune thyroiditis in rats with the synthetic peptide (2495-2511) of thyroglobulin. , 1993, Cellular immunology.

[35]  J. Guardiola,et al.  Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases. , 1993, Critical reviews in immunology.

[36]  A. Cooke,et al.  Identification of a thyroxine-containing self-epitope of thyroglobulin which triggers thyroid autoreactive T cells , 1991, The Journal of experimental medicine.

[37]  Eric O Long,et al.  HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals. , 1990, Journal of immunology.

[38]  T. Maudelonde,et al.  The Lancet: saturday 11 November 1989 , 1989 .

[39]  I. Todd,et al.  Occurrence of thyrocyte HLA class II expression in a wide variety of thyroid diseases: relationship with lymphocytic infiltration and thyroid autoantibodies. , 1988, The Journal of clinical endocrinology and metabolism.

[40]  D. Doniach,et al.  ABERRANT EXPRESSION OF HLA-DR ANTIGEN ON THYROCYTES IN GRAVES' DISEASE: RELEVANCE FOR AUTOIMMUNITY , 1983, The Lancet.

[41]  M. Feldmann,et al.  ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY , 1983, The Lancet.

[42]  W. Mayr,et al.  HLA-DR3 and HLA-DR5 associated thyrotoxicosis--two different types of toxic diffuse goiter. , 1983, The Journal of clinical endocrinology and metabolism.

[43]  N. Farid,et al.  A study of human leukocyte D locus related antigens in Graves' disease. , 1979, The Journal of clinical investigation.

[44]  N. Rose,et al.  Induction of autoimmunity in good and poor responder mice with mouse thyroglobulin and lipopolysaccharide , 1977, The Journal of experimental medicine.

[45]  A. Dayan,et al.  BIRTH CONTROL FOR PROBLEM PARENTS. , 1964, Lancet.